QBX258

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Memorial Sloan Kettering Cancer Center

Conditions

AsthmaBreast CancerUpper Extremity Lymphedema

Phase 2

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

CompletedNCT01479595

Novartis PharmaceuticalsAsthma

Start: 2012-02-29End: 2015-02-28Updated: 2016-08-01

Unknown Phase

Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)

CompletedNCT02494206

Memorial Sloan Kettering Cancer CenterBreast Cancer, Upper Extremity Lymphedema

Start: 2015-07-31End: 2018-05-31Updated: 2018-11-08